119 related articles for article (PubMed ID: 38679202)
21. Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size.
Aoki M; Sato M; Hirose K; Akimoto H; Kawaguchi H; Hatayama Y; Ono S; Takai Y
Radiat Oncol; 2015 Apr; 10():99. PubMed ID: 25897487
[TBL] [Abstract][Full Text] [Related]
22. Chest wall pain following lung stereotactic body radiation therapy using 48Gy in three fractions: A search for predictors.
Albers J; Parker W; Kildea J; Pembroke C; Faria S
Cancer Radiother; 2019 Apr; 23(2):98-103. PubMed ID: 30952561
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
25. Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT).
Murakami Y; Nakano M; Yoshida M; Hirashima H; Nakamura F; Fukunaga J; Hirose TA; Yoshioka Y; Oguchi M; Hirata H
J Radiat Res; 2018 May; 59(3):327-332. PubMed ID: 29800456
[TBL] [Abstract][Full Text] [Related]
26. Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus.
Sodji QH; Ko R; von Eyben R; Owen SG; Capaldi DPI; Bush K; Binkley MS; Alrowais F; Pickthorn B; Maxim PG; Gensheimer MF; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1144-1153. PubMed ID: 34942312
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with chest wall toxicity after accelerated partial breast irradiation using high-dose-rate brachytherapy.
Brown S; Vicini F; Vanapalli JR; Whitaker TJ; Pope DK; Lyden M; Bruggeman L; Haile KL; McLaughlin MP
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):801-5. PubMed ID: 22245195
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
30. Radiation-related Adverse Effects of CT-guided Implantation of
Ji Z; Jiang Y; Guo F; Peng R; Sun H; Wang P; Fan J; Wang J
Sci Rep; 2019 Oct; 9(1):14803. PubMed ID: 31616052
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
32. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver.
Andolino DL; Forquer JA; Henderson MA; Barriger RB; Shapiro RH; Brabham JG; Johnstone PA; Cardenes HR; Fakiris AJ
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):692-7. PubMed ID: 21288656
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
[TBL] [Abstract][Full Text] [Related]
35. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
[TBL] [Abstract][Full Text] [Related]
36. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
[TBL] [Abstract][Full Text] [Related]
37. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
